Company news
PepGen Inc. news in 2022
PepGen Inc.'s news releases, calls and decks from 2022, newest first.
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
December 6, 2022
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
November 13, 2022
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 9, 2022
PepGen to Participate in the Stifel 2022 Healthcare Conference
November 7, 2022
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
October 12, 2022
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
September 27, 2022
PepGen Appoints Habib Dable to Board of Directors
September 21, 2022
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 11, 2022
PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board
July 21, 2022
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments
June 15, 2022
PepGen Announces Pricing of Initial Public Offering
May 4, 2022
Decks in 2022
- Corporate Update (September 2022)
Corporate update · 24 slides · Sep 28, 2022